Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald increased their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. HC Wainwright began coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective for the company.

Vanda Pharmaceuticals Stock Up 4.2 %

NASDAQ VNDA opened at $5.19 on Monday. Vanda Pharmaceuticals has a twelve month low of $3.46 and a twelve month high of $6.75. The stock has a market cap of $302.63 million, a P/E ratio of -18.54 and a beta of 0.77. The company’s 50-day simple moving average is $4.81 and its 200 day simple moving average is $5.26.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VNDA. Price T Rowe Associates Inc. MD grew its holdings in Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 2,425 shares during the last quarter. Panagora Asset Management Inc. increased its holdings in shares of Vanda Pharmaceuticals by 4.3% in the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 2,509 shares in the last quarter. Verition Fund Management LLC raised its position in Vanda Pharmaceuticals by 7.8% in the 3rd quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Vanda Pharmaceuticals by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock worth $2,796,000 after buying an additional 3,473 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.